Update on the “Cobalt” Study
Vishal Patel, the lead researcher from Kings on the COBALT study, spoke at the Listen Group meeting on 15 November to update us on the status of the study.
The study involves 100 hospitals across Europe; Kings is one of only two hospitals in the UK who are involved and much of the scientific work will be carried out on the Kings campus. It is hoped to recruit 5,500 people to take part.
He explained that processes for the study have unfortunately been delayed. Answers have been awaited from the sponsor in Europe and unfortunately for the study, the success of the UK vaccination programme has meant that that many of us who applied no longer qualify to take part.
The recruitment window to take part in the study is that people should be 24-36 weeks post second dose vaccine and that they have not had their third/booster dose. Participants need to be aged 18 or over and have had their liver transplant at least six months ago. Anyone who has had PCR confirmed Covid infection is not eligible.
Vishal made it very clear that the most important thing was for people to get the booster as soon as it is available to them – their health was far more important than taking part in the study.
He thanked everyone who has expressed an interest in the study.
If you feel you meet the criteria above, please get in touch with Reva –revathi.arputham@nhs.net giving the following information:
- Full name:
- Address incl postcode:
- KCH hospital number or NHS number:
- Phone number (mobile preferably):
- Email address:
- Date of liver transplant:
- Date of COVID19 vaccine dose #1:
- Date of COVID19 vaccine dose #2:
- COVID19 vaccine dose #3 (booster dose) received: YES or NO?
- – if no, specify the date on which the booster dose planned:
- Any history of COVID19 infection: YES / NO
- – if yes, was this diagnosed by PCR i.e. throat and nasal swabs?
- Does the patient have a clinic appointment at KCH in the next 3 months: YES / NO
- – if yes, what dates and with which department?
